Meta's Creator Tools Boost Engagement but EU and Capex Risks Loom

What happened

Meta's latest push into advanced creator tools, highlighted by surging Edits app usage and AI adoption, is driving engagement and supporting a strong revenue outlook. However, the DeepValue report maintains a cautious stance, noting that the real test lies in Q1-Q2 2026 results, which must show sustained ad monetization despite EU regulatory tightening and a massive $115B-$135B capex ramp. The article's positive signals on AI adoption align with the report's view that AI is boosting ad performance, but do not alleviate the primary risk: that EU Less Personalized Ads changes could materially impact European revenue. Management's guidance for 2026 operating income to exceed 2025's and for capex to stay within range is the key accountability metric. Until these proofs emerge, the risk/reward remains balanced, warranting a wait-and-see approach.

Implication

The article reinforces that Meta's AI investments are driving near-term engagement and revenue growth, but the DeepValue report's core thesis remains intact: the stock's next move depends on whether ad monetization holds up after EU policy changes (starting Q1'26) and whether management can execute the capex plan without upward revisions. Until these two uncertainties resolve, the stock is fairly priced at ~$634 with limited upside catalysts. Investors should hold current positions but avoid adding until Q1 2026 results confirm that impressions and price per ad remain positive and that capex guidance is not revised upward. The bull case (AI-driven outperformance) is consistent with the article, but the bear case (EU disruption and capex shock) is equally plausible, making the risk/reward unattractive for new commitments.

Thesis delta

The news of rising creator tool adoption and AI-driven engagement provides incremental support for the AI-ad boost narrative but does not change the fundamental uncertainty around EU regulatory impact and capex execution. The investment thesis remains dependent on Q1-Q2 2026 data points, and the WAIT rating is reaffirmed.